Skip to main content

LCD L39027: Respiratory Pathogen Panel Testing

LCD L39027, Respiratory Pathogen Panel Testing, is the Local Coverage Determination that Wellpoint Federal applies to claims from 10 states (CT, IL, MA, ME, MN, NH, NY, RI and others), effective 2026-04-01 and first in force 2021-12-01. The policy text runs 368 words, and its billing and coding article A58741 lists 192 ICD-10-CM codes that support medical necessity for 13 procedure codes. 2 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 192 covered ICD-10-CM codes: 1 fewer code than L38916 (Novitas Solutions, Inc., 193 codes, revised 2021-07-11) and 1 fewer code than L38918 (First Coast Service Options, Inc., 193 codes, revised 2021-07-11).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wellpoint Federal
States and territories
10
CT IL MA ME MN NH NY RI VT WI
Revision effective
2026-04-01
Original effective
2021-12-01
Policy text
368 words
Covered ICD-10 codes (articles)
192

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39027
ContractContractorTypeStates
06102Wellpoint FederalMAC - Part BIL
06202Wellpoint FederalMAC - Part BMN
06302Wellpoint FederalMAC - Part BWI
13102Wellpoint FederalA and B and HHH MACCT
13202Wellpoint FederalA and B and HHH MACNY
13282Wellpoint FederalA and B and HHH MACNY
13292Wellpoint FederalA and B and HHH MACNY
14112Wellpoint FederalA and B and HHH MACME
14212Wellpoint FederalA and B and HHH MACMA
14312Wellpoint FederalA and B and HHH MACNH
14512Wellpoint FederalA and B and HHH MACVT
14412Wellpoint FederalA and B and HHH MACRI

Billing and coding article A58741: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A58741 (Billing and Coding: Respiratory Pathogen Panel Testing) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A58741: Billing and Coding: Respiratory Pathogen Panel Testing (Billing and Coding, effective 2026-04-01)

Covered ICD-10-CM codes
192
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
13
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A58741
ICD-10-CMDescription (FY2027)
B97.29Other coronavirus as the cause of diseases classified elsewhere
D80.0Hereditary hypogammaglobulinemia
D80.1Nonfamilial hypogammaglobulinemia
D80.2Selective deficiency of immunoglobulin A [IgA]
D80.3Selective deficiency of immunoglobulin G [IgG] subclasses
D80.4Selective deficiency of immunoglobulin M [IgM]
D80.5Immunodeficiency with increased immunoglobulin M [IgM]
D80.6Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia
D80.8Other immunodeficiencies with predominantly antibody defects
D81.0Severe combined immunodeficiency [SCID] with reticular dysgenesis
D81.1Severe combined immunodeficiency [SCID] with low T- and B-cell numbers
D81.2Severe combined immunodeficiency [SCID] with low or normal B-cell numbers
D81.31Severe combined immunodeficiency due to adenosine deaminase deficiency
D81.32Adenosine deaminase 2 deficiency
D81.39Other adenosine deaminase deficiency
D81.4Nezelof's syndrome
D81.5Purine nucleoside phosphorylase [PNP] deficiency
D81.6Major histocompatibility complex class I deficiency
D81.7Major histocompatibility complex class II deficiency
D81.810Biotinidase deficiency
D81.818Other biotin-dependent carboxylase deficiency
D81.89Other combined immunodeficiencies
D82.0Wiskott-Aldrich syndrome
D82.1Di George's syndrome

Procedure codes: 0115U, 0202U, 0223U, 0225U, 0528U, 0563U, 0564U, 87428, 87631, 87632, 87633, 87636, 87637.

Coverage indications, limitations and medical necessity

Compliance with the provisions in this policy may be monitored and addressed through post payment data analysis and subsequent medical review audits.

History/Background and/or General Information

Diagnostic testing for identification of pathogens that are causative for respiratory infections has evolved over the years. The aim is for rapid, accurate, and sensitive identification in an effort to improve patient outcomes through improved clinical decision making. These new technologies include nucleic acid-based amplification techniques. The focus of this LCD is respiratory pathogen panel testing, which typically includes detection for multiple virus pathogens by amplification of target DNA and is currently the most popular technique that can provide rapid, accurate, and sensitive results. 1

Even with the widespread use of respiratory pathogen panel testing, only a few methods are available that not only detect respiratory pathogens but are also U.S. Food and Drug Administration (FDA) approved. Please see the FDA link for approved/cleared respiratory pathogen panel tests. https://www.fda.gov/. 2 It is recognized that labs may not have FDA approval/clearance of their products, i.e. laboratory developed tests (LDTs). At the time of this publication, tests are not limited to FDA approved/cleared products only. Coverage for tests is based on demonstration of analytical and clinical validity and clinical utility at a level that meets the Medicare medically reasonable and necessary requirement.

Covered Indications

Respiratory pathogen panel testing in the outpatient by a Part B provider (e.g., physician's office, independent clinical laboratory) will be considered medically reasonable and necessary when all of the following are met:

• Panels with ≤5 respiratory pathogens are performed, and BOTH of the following criteria are met:

• The outpatient setting is equipped to deliver timely results AND ,

• For patients where the test result aids clinical management with the goal of an improved health outcome for the patient.

Limitations

The following is considered not medically reasonable and necessary:

• Panels with >5 respiratory pathogens performed in the Part B outpatient setting. 3

Notice: Services performed for any given diagnosis must meet all of the indications and limitations stated in this policy, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.

Summary of evidence (opening)

Introduction

This evidence review focuses on respiratory pathogen panel testing in the outpatient setting and whether the evidence is adequate to draw conclusions about improved health outcomes for the Medicare population. In general, improved health outcomes of interest include patient mortality and morbidity, as well as patient quality of life and function. The current clinical evidence is based on guideline recommendations and clinical studies that demonstrate the clinical utility of this testing. Specific outcomes of these trials in the outpatient setting are focused on accurate detection and identification of the pathogens in an effort to help guide clinical decision making. In other words, does performance of this test in the outpatient setting affect patient care, and ultimately, lead to reduced morbidity and mortality from respiratory infections in the Medicare population. Accurate, rapid test results have the potential to alter clinical management, such as initial medication prescription and safe medication de-escalation, which will result in improved patient health outcomes.

Internal Technology Assessment

PubMed® was searched for prospective clinical trials that included the terms molecular and respiratory. The studies that were found using these terms were then screened for applicability to the adult outpatient population. Only two studies were found that met the inclusion criteria. A search utilizing the terms molecular and pneumonia found no new studies. The terms panel and respiratory had 121 results and respiratory and immunocompromised had 59 results. The studies were then screened for inclusion of adults and outpatient settings. Guidelines were searched for respiratory infections, especially those which included patients who are immunocompromised. Additional studies were found upon review of the bibliographies within other search criteria. For inclusion in review, studies must be published in the English language and be specific to the human population. All countries of origin were included if broad inclusion for the clinical studies met the criteria. Ultimately, prospective studies that included adults, had identifiable outpatients, and had clinical utility outcomes for respiratory pathogen panel tests that primarily change the clinician decision making as the surrogate for patient outcomes of morbidity and mortality were included.

The contractor cites 35 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2021-12-01
Current revision effective
2026-04-01
MCD version
8

Other related documents: A58890 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39027 cover?

Even with the widespread use of respiratory pathogen panel testing, only a few methods are available that not only detect respiratory pathogens but are also U.S. Food and Drug Administration (FDA) approved. Please see the FDA link for approved/cleared respiratory pathogen panel tests. https://www.fda.gov/. 2 It is recognized that labs may not have FDA approval/clearance of their products, i.e. laboratory developed… The full 368-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39027 apply to?

Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; 2 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39027?

The companion billing and coding article A58741 lists 192 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L39027?

A denial under LCD L39027 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A58741's 192 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.